Suven Life Sciences Complete Financial Statements
In FY2026, Suven Life Sciences (SUVEN) reported revenue ₹8 Cr, net profit ₹-46 Cr and EPS ₹-2.02, with a net profit margin of -575.0% and ROE of -7.8%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore SUVEN value investing to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SUVEN Revenue, Net Profit & EBITDA — Year-on-Year Growth
SUVEN YoY (Mar 2025 vs Mar 2026) — revenue +166.7%, net profit -4.5%, EBITDA -2.3%, expenses +15.6%. Review Suven Life Sciences price earnings to evaluate earnings-based valuation against sector peers.
SUVEN Income Statement — Revenue, EBITDA & Net Profit
Suven Life Sciences revenue ₹8 Cr, EBITDA ₹-44 Cr, net profit ₹-46 Cr, EPS ₹-2.02 (2026) — net profit margin -575.0%. For live price, earnings ratios and company overview, see Suven Life Sciences stock price NSE.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 5 | 3 | 3 | 6 | 7 | 7 | 5 | 3 | 16 | 8 | 9 | 9 | 5 | 4 | 10 | 5 | 2 | 3 | 7 | 5 | 11 | 12 | 4 | 3 | 4 | 8 | 4 | 9 | 96 | 200 | 9 |
| Expenses | 52 | 81 | 45 | 53 | 106 | 55 | 33 | 32 | 41 | 27 | 34 | 32 | 49 | 26 | 24 | 25 | 55 | 29 | 23 | 45 | 37 | 27 | 34 | 16 | 28 | 23 | 51 | 44 | 30 | 79 | 146 | 22 |
| EBITDA | -44 | -76 | -43 | -50 | -101 | -48 | -26 | -27 | -38 | -11 | -26 | -22 | -40 | -22 | -20 | -15 | -49 | -27 | -20 | -38 | -32 | -15 | -22 | -12 | -25 | -19 | -42 | -39 | -22 | 17 | 54 | -13 |
| Operating Profit Margin % | -3331.00% | -8671.00% | -2981.00% | -2714.00% | -3678.00% | -2032.00% | -1267.00% | -3023.00% | -2435.00% | -768.00% | -1208.00% | -737.00% | -1885.00% | -494.00% | -467.00% | -595.00% | -1720.00% | -2341.00% | -1383.00% | -2118.00% | -733.00% | -196.00% | -290.00% | -994.00% | -1764.00% | -1517.00% | -2025.00% | -2635.00% | -999.00% | 11.00% | 24.00% | -936.00% |
| Depreciation | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 6 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit Before Tax | -46 | -77 | -44 | -52 | -102 | -50 | -28 | -28 | -39 | -13 | -28 | -24 | -42 | -23 | -21 | -16 | -51 | -28 | -22 | -39 | -34 | -17 | -23 | -13 | -26 | -20 | -44 | -40 | -23 | 11 | 47 | -14 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 2 | -3 | -2 | 0 | -4 | -14 | 0 | 7 | 21 | 0 |
| Net Profit | -46 | -77 | -44 | -52 | -102 | -50 | -27 | -28 | -39 | -13 | -28 | -24 | -42 | -23 | -21 | -16 | -51 | -28 | -22 | -39 | -34 | -16 | -26 | -11 | -24 | -20 | -39 | -26 | -23 | 4 | 26 | -14 |
| Earnings Per Share (₹) | -2.02 | -3.48 | -2.02 | -2.36 | -4.55 | -2.27 | -1.22 | -1.29 | -1.79 | -0.58 | -1.17 | -1.10 | -1.92 | -1.51 | -1.63 | -1.12 | -2.90 | -2.22 | -1.70 | -3.08 | -2.50 | -1.23 | -2.01 | -0.82 | -1.92 | -1.56 | -3.10 | -2.05 | -1.79 | 0.30 | 2.04 | -1.13 |
SUVEN Balance Sheet — Assets, Liabilities & Shareholders' Equity
SUVEN total assets ₹624 Cr, total equity ₹591 Cr, total liabilities ₹ Cr (2026) — ROE -7.8%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 624 | 135 | 285 | 389 | 108 | 128 | 182 | 303 | 919 | 816 | 752 | 773 |
| Current Assets | 547 | 76 | 257 | 252 | 67 | 103 | 66 | 281 | 570 | 492 | 428 | 477 |
| Fixed Assets | 77 | 60 | 28 | 37 | 38 | 21 | 25 | 22 | 308 | 306 | 305 | 172 |
| Capital Work in Progress | 4 | 0 | 0 | 0 | 4 | 5 | 0 | 0 | 25 | 10 | 7 | 107 |
| Investments | 0 | 22 | 76 | 46 | 45 | 0 | 0 | 223 | 279 | 301 | 0 | 0 |
| Other Assets | 0 | 53 | 181 | 305 | 22 | 103 | 157 | 58 | 308 | 199 | 439 | 494 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 2 | 2 | 1 | 3 | 4 | 5 | 12 | 25 | 30 | 30 | 46 | 86 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 591 | 110 | 270 | 375 | 96 | 108 | 143 | 239 | 767 | 667 | 595 | 559 |
| Share Capital | 26 | 22 | 22 | 22 | 15 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 565 | 88 | 248 | 354 | 82 | 58 | 131 | 226 | 755 | 654 | 583 | 547 |
SUVEN Cash Flow Statement — Operating, Investing & Financing
Suven Life Sciences operating cash flow ₹-154 Cr, investing ₹155 Cr, financing ₹-1 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -154 | -116 | -116 | -128 | -96 | -135 | -53 | 70 | 109 | 68 | 143 |
| Investing Activities | 155 | 94 | -248 | -22 | 56 | 146 | 30 | -1 | -311 | -39 | -110 |
| Financing Activities | -1 | -1 | 396 | 146 | 35 | 3 | 5 | -52 | -30 | -68 | 179 |
| Net Cash Flow | 0 | -22 | 32 | -4 | -5 | 14 | -18 | 17 | -232 | -39 | 212 |